Month: December 2020

Överskott för staten i november 2020Statens betalningar resulterade i ett överskott på 40,4 miljarder kronor i november. Riksgäldens prognos var ett överskott på 20,5 miljarder kronor. Skillnaden beror på lägre utgifter och högre skatteinkomster än beräknat.  På grund av ett fel publicerades rapporten Sveriges statsskuld november 2020 i förtid på söndag den 6 december istället för som planerat måndag den 7 december kl. 09.30. Riksgälden tidigarelägger därför hela publiceringen av utfallet för statens betalningar och statsskuldens storlek i november 2020.Det primära saldot blev 20,4 miljarder kronor högre än prognos. Skatteinkomsterna var cirka 7 miljarder kronor högre än beräknat. Därutöver var utbetalningarna från ett antal myndigheter lägre än beräknat.Riksgäldens nettoutlåning till myndigheter m.fl. var 0,8 miljarder kronor lägre än...

67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated activity, both as a monotherapy and as add on to ruxolitinib, in second-line or later settingsTranslational data supports potential disease-modifying effects of CPI-0610CAMBRIDGE, Mass., Dec. 06, 2020 (GLOBE NEWSWIRE) — Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that two oral presentations and three posters relating to the Phase 2 MANIFEST and the Phase 3 MANIFEST-2 clinical trials of CPI-0610 in myelofibrosis (MF) were presented at the American Society of Hematology (ASH) Annual Meeting and Exposition. The preliminary data in these presentations are based on a data cutoff of September 29, 2020, and reflect an analysis of clinical activity in 63 first-line (1L)...

~Five presentations related to Kiadis’ K-NK cell therapy platform will be presentedat the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition~An oral presentation (abstract #68) presents data that show multiple infusions of FC21-NK cells in patients with relapsed and refractory acute myeloid leukemia (R/R AML) yielded impressive outcomes with no infusion reactions or toxicities A poster presentation (abstract #825) describes data demonstrating NKTR-255 significantly enhanced the ADCC of expanded NK cells with anti-CD20 type I and type II antibodies against CLL, FL and rituximab-resistant BL cellsA poster presentation (abstract #2151) provides details of a phase I pilot study in CML patients to evaluate safety and examine if adding K-NK003 to ongoing Tyrosine kinase inhibitors (TKI) therapy leads to achieving MRD negative...

Strengur hf. published a press release 2 December 2020, announcing that the offer document for the takeover bid of Strengur hf. to Skeljungur hf.’s shareholders would be published on Sunday 6 December 2020. Attached is the Official Offer Document.AttachmentSkeljungur_opinbert tilboðsyfirlit

Strengur hf. birti auglýsingu í fjölmiðlum þann 2. desember 2020 þar sem boðað var að tilboðsyfirlit vegna yfirtökutilboðs Strengs hf. til hluthafa Skeljungs hf. yrði birt sunnudaginn 6. desember 2020. Tilboðsyfirlitið má finna í viðhengi. ViðhengiSkeljungur_opinbert tilboðsyfirlit

VANCOUVER, British Columbia, Dec. 06, 2020 (GLOBE NEWSWIRE) — SouthGobi Resources Ltd. (TSX: SGQ, HK: 1878) (“SouthGobi” or the “Company”) announces that the Company will postpone its annual general meeting of the shareholders of the Company in 2020 (the “2020 AGM”) to January 21, 2021 and has obtained the requisite approval from the Toronto Stock Exchange (“TSX”) on November 7, 2020 to extend the time within which to hold its 2020 AGM in order to permit the Company to convene the 2020 AGM on or before January 21, 2021.Reference is made to the announcement of the Company dated May 12, 2020 (the “Announcement”) and capitalized terms used herein, unless otherwise defined, shall have the same meaning as those defined in the Announcement. As disclosed in the Announcement, the Company (i) obtained an Order from the British Columbia Registrar...

Cellectis’ Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease2 out of 3 Patients at DL1 Achieved CR/CRi and 1 out of 2 Patients at DL2 Achieved a Significant Reduction in Bone Marrow BlastsBALLI-01 Currently Enrolling at DL2 with Addition of Alemtuzumab to the FC Lymphodepletion Regimen; Next Data Update Expected in 2021NEW YORK, Dec. 05, 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced preliminary results from Cellectis’ dose escalation Phase 1 BALLI-01 study of UCART22 product candidate in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) were presented...

Le produit candidat UCART22 de Cellectis a été administré en toute sécurité dans l’étude de Phase I BALLI-01 sans manifestation de toxicité limitant la dose, ni de maladie du greffon contre l’hôte2 patients sur 3 au palier de dose 1 ont atteint une rémission complète avec une récupération hématologique incomplète, et 1 patient sur 2 au palier de dose 2 a atteint une réduction significative des blastes dans la moelle osseuseInclusion de patients en cours dans l’essai clinique BALLI-01 au palier de dose 2 incorporant l’alemtuzumab au régime de lymphodéplétion composé de fludarabine et cyclophosphamide ; prochaine publication des données clinique prévue en 2021NEW YORK, 05 déc. 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth : ALCLS – Nasdaq : CLLS), une société biopharmaceutique spécialisée dans le développement...

Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALLConference call and webcast to be held Monday, December 7, 2020 at 4:00 pm ET / 9:00 pm GMTLONDON, Dec. 05, 2020 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on its AUTO1 program, the company’s CAR T cell therapy being investigated in the ongoing ALLCAR Phase 1 study in relapsed / refractory adult B-Acute Lymphocytic Leukemia (ALL), during the American Society of Hematology (ASH) All-Virtual Annual Meeting, held between December 5-8, 2020.As of the November 12, 2020 data cut-off date, 20 patients with r/r ALL had received AUTO1. AUTO1 was well tolerated,...

– 9 of 14 Patients Showed Reduction in Tumor Size, Including Two Recently Reported Complete Responses –– Company to Host Conference Call and Webcast Today at 2:00 p.m. ET –MOUNTAIN VIEW, Calif., Dec. 05, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the presentation of preliminary clinical results from the Company’s Phase 1 trial evaluating IGM-2323, a bispecific IgM antibody targeting CD20 x CD3, at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. The data was featured today in a poster presentation titled “Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody IGM-2323 (anti-CD20 x anti-CD3) in...